Delanie Cassell

Title: Delanie Cassell: Innovator in Cancer Treatment

Introduction

Delanie Cassell is a prominent inventor based in San Anselmo, California. She has made significant contributions to the field of cancer treatment through her innovative research and development. Her work focuses on utilizing the Parapox B2L protein to enhance immune responses and provide therapeutic options for cancer patients.

Latest Patents

Delanie holds a patent for the "Use of Parapox B2L protein to treat cancer and modify immune responses." This patent describes a purified envelope protein termed 'B2L' that can be used as a monotherapeutic agent. The B2L protein also serves as a valuable tool in screening methods to identify potential therapeutic agents for modulating a subject's immune response to the B2L protein. She has 1 patent to her name.

Career Highlights

Delanie Cassell is currently employed at Bayer Pharmaceuticals Corporation, where she continues to advance her research in cancer therapies. Her work at Bayer has positioned her as a key player in the pharmaceutical industry, contributing to innovative solutions for complex health challenges.

Collaborations

Delanie collaborates with notable colleagues, including Jeffrey Tepper and Isa Samuels. These partnerships enhance her research efforts and foster a collaborative environment for innovation.

Conclusion

Delanie Cassell is a trailblazer in the field of cancer treatment, with her groundbreaking work on the B2L protein paving the way for new therapeutic approaches. Her contributions to Bayer Pharmaceuticals Corporation and the scientific community are invaluable.